Why advanced therapy medicinal products struggle in clinical translation: an in-depth analysis of developmental challenges in the EU - Top-Institutions - MDSpire

Why advanced therapy medicinal products struggle in clinical translation: an in-depth analysis of developmental challenges in the EU

  • By

  • Charlotte Van Isterdael

  • Edurne Mugarza

  • Piret Fischer

  • Koen Debackere

  • Peter Vandenberghe

  • Silvia Martin Lluesma

  • Johan Van Eldere

  • Isabelle Huys

  • June 2, 2026

  • 0 min

Share

Top Institutions in General Medicine

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Oncology
    • Pharmacology

  • #2

    KU Leuven
    KU Leuven

    Leuven, Belgium

    Key Differentiators

    • Pharmacology
    • Biomedical Research

  • #3

    University of Colorado Comprehensive Cancer Center
    University of Colorado Comprehensive Cancer Center

    Aurora, CO

    Key Differentiators

    • Oncology
    • Pharmacology

Original Source(s)

Why advanced therapy medicinal products struggle in clinical translation: an in-depth analysis of developmental challenges in the EU

  • by Charlotte Van Isterdael, Edurne Mugarza, Piret Fischer, Koen Debackere, Peter Vandenberghe, Silvia Martin Lluesma, Johan Van Eldere, Isabelle Huys

  • June 2, 2026

Related Content

TEASE Program Builds Case for Gildeuretinol in Stargardt

Philip J. Ferrone, MD, FASRS, reviewed data on gildeuretinol and discussed the ongoing NORTHSTAR pivotal trial at Retina World Congress.

Biotech exec Jeremy Levin on the industry’s strategic turning point

The nitrovinyl moiety determines the cyto- and genotoxic profiles of β-nitrostyrene derivatives: evidence from in silico and in vitro evaluation